HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients.

@article{Mason2005HMGcoenzymeAR,
  title={HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients.},
  author={Nancy A. Mason and George R. Bailie and Sudtida S Satayathum and Jennifer Bragg-Gresham and Takashi Akiba and Tadao Akizawa and Christian Combe and Hugh C Rayner and Akira Saito and Brenda W. Gillespie and Eric W. Young},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2005},
  volume={45 1},
  pages={119-26}
}
BACKGROUND Cardiovascular disease is the most common cause of mortality in patients with end-stage renal disease. Cardiovascular benefits of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been clearly established in the general population, but not in dialysis patients. This study examined statin prescription patterns and assessed the relationship between statin prescription and clinical outcomes in hemodialysis (HD) patients. METHODS Data were analyzed from the… CONTINUE READING

From This Paper

Topics from this paper.
54 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…